# Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product

> **NCT02338375** · EARLY_PHASE1 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 28 (actual)

## Conditions studied

- Osteochondral Lesion of Talus

## Interventions

- **BIOLOGICAL:** Cartistem

## Key facts

- **NCT ID:** NCT02338375
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2015-08
- **Final completion:** 2015-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338375, "Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02338375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*